These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26818046)

  • 1. Could Adult European Pharmacoresistant Epilepsy Patients Be Treated With Higher Doses of Zonisamide?
    Miro J; Jaraba S; Juvany R; Santurino M; Cobo S; Falip M
    Clin Neuropharmacol; 2016; 39(3):121-4. PubMed ID: 26818046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide for refractory juvenile absence epilepsy.
    Velizarova R; Crespel A; Genton P; Serafini A; Gelisse P
    Epilepsy Res; 2014 Sep; 108(7):1263-6. PubMed ID: 24907183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.
    Marinas A; Villanueva V; Giráldez BG; Molins A; Salas-Puig J; Serratosa JM
    Epileptic Disord; 2009 Mar; 11(1):61-6. PubMed ID: 19264587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy.
    Schulze-Bonhage A
    Expert Rev Neurother; 2015; 15(8):857-65. PubMed ID: 26144543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
    Doğan EA; Genç E; Genç BO; Erdoğan Ç
    Epilepsy Behav; 2017 Nov; 76():19-23. PubMed ID: 28927711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy.
    Lee YJ; Kang HC; Seo JH; Lee JS; Kim HD
    Brain Dev; 2010 Mar; 32(3):208-12. PubMed ID: 19304420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures.
    Sackellares JC; Ramsay RE; Wilder BJ; Browne TR; Shellenberger MK
    Epilepsia; 2004 Jun; 45(6):610-7. PubMed ID: 15144425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.
    Brodie MJ; Duncan R; Vespignani H; Solyom A; Bitenskyy V; Lucas C
    Epilepsia; 2005 Jan; 46(1):31-41. PubMed ID: 15660766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term retention rate of zonisamide in patients with epilepsy: an observational study.
    Kim DW; Choi K; Moon HS; Oh J
    Clin Neuropharmacol; 2014; 37(5):133-5. PubMed ID: 25229169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM.
    Hamer H; Baulac M; McMurray R; Kockelmann E
    Seizure; 2016 Jan; 34():66-73. PubMed ID: 26735004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.
    Peters DH; Sorkin EM
    Drugs; 1993 May; 45(5):760-87. PubMed ID: 7686468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy.
    Wallander KM; Ohman I; Dahlin M
    Neuropediatrics; 2014 Dec; 45(6):362-70. PubMed ID: 25133701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre.
    Catarino CB; Bartolini E; Bell GS; Yuen AW; Duncan JS; Sander JW
    Epilepsy Res; 2011 Sep; 96(1-2):39-44. PubMed ID: 21601427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide in the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2010 Jan; 11(1):115-26. PubMed ID: 20001433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of zonisamide: our experience.
    Yamauchi T; Aikawa H
    Seizure; 2004 Dec; 13 Suppl 1():S41-8; discussion S49. PubMed ID: 15511689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and monitoring of patients treated with zonisamide: the OZONE study.
    Dupont S; Biraben A; Lavernhe G; Marquet T; Allaf B
    Epileptic Disord; 2013 Sep; 15(3):278-88. PubMed ID: 23906691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study.
    Helmstaedter C; Stefan H; Witt JA
    Epileptic Disord; 2011 Sep; 13(3):263-76. PubMed ID: 21914589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice.
    Park KM; Lee BI; Shin KJ; Ha SY; Park J; Kim SE; Kim SE
    J Clin Neurosci; 2019 Mar; 61():44-47. PubMed ID: 30446366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.